For Researchers

Defining sarcopenia: some caveats and challenges

D. Sanchez-Rodriguez, E. Marco, A.J. Cruz-Jentoft

Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):127-132. doi: 10.1097/MCO.0000000000000621.

The aim was to summarize the latest advances and caveats in defining sarcopenia and discuss the implications of the most recent worldwide initiatives which are trying to harmonize the definition.

Musculoskeletal adaptations to strength training in frail elderly: a matter of quantity or quality?

S.N. Aas, M. Breit, S. Karsrud, et al.

J Cachexia Sarcopenia Muscle. 2020 Feb 24. doi: 10.1002/jcsm.12543. [Epub ahead of print]

The aim of this study was to investigate the effect of heavy-load strength training on a broad number of factors related to specific strength in frail elderly.

Sex-different associations between serum homocysteine, high-sensitivity C-reactive protein and sarcopenia: Results from I-Lan Longitudinal Aging Study

W.J. Lee, L.N. Peng, C.H. Loh, et al.

Exp Gerontol. 2020 Apr;132:110832. doi: 10.1016/j.exger.2020.110832. Epub 2020 Jan 8.

Both serum homocysteine and high sensitivity C - reactive protein (hsCRP) are inflammatory markers related to vascular aging. Little was known about relationship between hsCRP and homocysteine and sarcopenia. The study aimed to explore the association between these two biomarkers and sarcopenia and its components.

Which one came first: movement behavior or frailty? A cross-lagged panel model in the Toledo Study for Healthy Aging

A. Mañas, B. Del Pozo-Cruz, I. Rodríguez-Gómez, et al.

J Cachexia Sarcopenia Muscle. 2020 Jan 8. doi: 10.1002/jcsm.12511. [Epub ahead of print]

This study aimed to determine the potential bidirectionality of the relationship between accelerometer-assessed between moderate-to-vigorous physical activity (MVPA), sedentary behaviour (SB), and frailty over time in older adults.

Inflammatory biomarkers of frailty

M. Vatic, S. von Haehling, N. Ebner

Exp Gerontol. 2020;133:110858. doi: 10.1016/j.exger.2020.110858. Epub 2020 Jan 31.

This review summarizes the present knowledge of inflammatory biomarkers that are considered promising tools to evaluate frailty.

ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty

L. Rodriguez-Mañas, I. Araujo de Carvalho, S. Bhasin,et al.

J Frailty Aging. 2020;9(1):4-8. doi: 10.14283/jfa.2019.32.

The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world -- met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia.

Pages